Achieve Life Sciences Inc (ACHV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) has a cash flow conversion efficiency ratio of -0.835x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.98 Million) by net assets ($21.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Achieve Life Sciences Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Achieve Life Sciences Inc (ACHV) total liabilities for a breakdown of total debt and financial obligations.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Selvita S.A.
WAR:SLV
|
0.069x |
|
Jih Lin Technology Co Ltd
TW:5285
|
0.010x |
|
BLE KEDROS REIC EO 1
F:N67
|
N/A |
|
Northcliff Resources Ltd
TO:NCF
|
-0.049x |
|
Smith-Midland Corp
NASDAQ:SMID
|
0.179x |
|
Aimia Inc
TO:AIM
|
0.110x |
|
Hung -Gu Oil Ltd
KQ:024060
|
0.020x |
|
Kopla Co. Ltd
KQ:126600
|
0.008x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see ACHV market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.52 Million | $-49.47 Million | -2.299x | -61.38% |
| 2024-12-31 | $20.90 Million | $-29.77 Million | -1.424x | -108.43% |
| 2023-12-31 | $-1.45 Million | $-24.48 Million | 16.905x | +473.62% |
| 2022-12-31 | $8.30 Million | $-37.57 Million | -4.525x | -330.99% |
| 2021-12-31 | $28.04 Million | $-29.44 Million | -1.050x | -190.52% |
| 2020-12-31 | $37.29 Million | $-13.47 Million | -0.361x | +57.13% |
| 2019-12-31 | $18.05 Million | $-15.22 Million | -0.843x | -25.40% |
| 2018-12-31 | $15.80 Million | $-10.62 Million | -0.672x | +41.84% |
| 2017-12-31 | $7.88 Million | $-9.11 Million | -1.156x | +26.15% |
| 2016-12-31 | $18.97 Million | $-29.68 Million | -1.565x | -543.84% |
| 2015-12-31 | $37.44 Million | $-9.10 Million | -0.243x | +52.17% |
| 2014-12-31 | $34.06 Million | $-17.31 Million | -0.508x | +47.37% |
| 2013-12-31 | $37.21 Million | $-35.93 Million | -0.965x | -46.97% |
| 2012-12-31 | $66.21 Million | $-43.49 Million | -0.657x | -0.15% |
| 2011-12-31 | $30.89 Million | $-20.26 Million | -0.656x | -7.84% |
| 2010-12-31 | $44.12 Million | $-26.84 Million | -0.608x | -140.04% |
| 2009-12-31 | $22.96 Million | $34.88 Million | 1.519x | +232.16% |
| 2008-12-31 | $10.71 Million | $-12.31 Million | -1.149x | -57.15% |
| 2007-12-31 | $31.90 Million | $-23.34 Million | -0.731x | -59.96% |
| 2006-12-31 | $43.04 Million | $-19.68 Million | -0.457x | -92.89% |
| 2005-12-31 | $35.26 Million | $-8.36 Million | -0.237x | +69.07% |
| 2004-12-31 | $19.08 Million | $-14.62 Million | -0.766x | -49.34% |
| 2003-12-31 | $19.31 Million | $-9.91 Million | -0.513x | +22.41% |
| 2002-12-31 | $15.72 Million | $-10.40 Million | -0.661x | -876.37% |
| 2001-12-31 | $14.67 Million | $1.25 Million | 0.085x | +118.24% |
| 2000-12-31 | $8.51 Million | $-3.97 Million | -0.467x | -4570.19% |
| 1999-12-31 | $10.00 Million | $-100.00K | -0.010x | +99.27% |
| 1998-12-31 | $7.50 Million | $-10.30 Million | -1.373x | -1914.76% |
| 1997-12-31 | $18.50 Million | $1.40 Million | 0.076x | -63.68% |
| 1996-12-31 | $16.80 Million | $3.50 Million | 0.208x | +129.11% |
| 1995-12-31 | $10.90 Million | $-7.80 Million | -0.716x | -284.01% |
| 1994-12-31 | $-9.00 Million | $-3.50 Million | 0.389x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sop… Read more